{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:32:09Z","timestamp":1784590329551,"version":"3.55.0"},"reference-count":122,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG067788"],"award-info":[{"award-number":["R01AG067788"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.expneurol.2022.114288","type":"journal-article","created":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T13:32:00Z","timestamp":1669469520000},"page":"114288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery"],"prefix":"10.1016","volume":"360","author":[{"given":"Aaron","family":"del Pozo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Barker-Haliski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2022.114288_bb0005","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1111\/bph.15181","article-title":"Interactions between cannabidiol and Delta(9) -tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome","volume":"177","author":"Anderson","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0010","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/can.2019.0005","article-title":"Cannabidiol-enriched extract reduced the cognitive impairment but not the epileptic seizures in a Lafora disease animal model","volume":"5","author":"Aso","year":"2020","journal-title":"Cannabis Cannabinoid. Res."},{"key":"10.1016\/j.expneurol.2022.114288_bb0015","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.nbd.2010.06.004","article-title":"Inflammation enhances epileptogenesis in the developing rat brain","volume":"40","author":"Auvin","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"Suppl. 3","key":"10.1016\/j.expneurol.2022.114288_bb0020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1528-1167.2010.02606.x","article-title":"Inflammation induced by LPS enhances epileptogenesis in immature rat and may be partially reversed by IL1RA","volume":"51","author":"Auvin","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114288_bb0025","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1038\/ncomms3410","article-title":"Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment","volume":"4","author":"Baraban","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.expneurol.2022.114288_bb0030","first-page":"1","article-title":"How do we choose the appropriate animal model for antiseizure therapy development?","author":"Barker-Haliski","year":"2019","journal-title":"Expert Opin. Drug Discovery"},{"key":"10.1016\/j.expneurol.2022.114288_bb0040","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/978-94-017-8914-1_24","article-title":"What are the arguments for and against rational therapy for epilepsy?","volume":"813","author":"Barker-Haliski","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0045","series-title":"Development of an Antiepileptogenesis Drug Screening Platform: Effects of Everolimus and Phenobarbital","author":"Barker-Haliski","year":"2021"},{"key":"10.1016\/j.expneurol.2022.114288_bb0050","article-title":"Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, modifies acute seizure burden and chronic epilepsy-related behavioral deficits following Theiler's virus infection in mice","volume":"222","author":"Barker-Haliski","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2022.114288_bb0055","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s40265-015-0395-9","article-title":"Disease modification in epilepsy: from animal models to clinical applications","volume":"75","author":"Barker-Haliski","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.expneurol.2022.114288_bb0060","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1111\/epi.13577","article-title":"Acute treatment with minocycline, but not valproic acid, improves long-term behavioral outcomes in the Theiler's virus model of temporal lobe epilepsy","volume":"57","author":"Barker-Haliski","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114288_bb0065","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1007\/s11064-017-2227-7","article-title":"Validation of a preclinical drug screening platform for Pharmacoresistant epilepsy","volume":"42","author":"Barker-Haliski","year":"2017","journal-title":"Neurochem. Res."},{"issue":"Suppl. 3","key":"10.1016\/j.expneurol.2022.114288_bb0070","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/epi.13785","article-title":"Neuroinflammation in epileptogenesis: insights and translational perspectives from new models of epilepsy","volume":"58","author":"Barker-Haliski","year":"2017","journal-title":"Epilepsia"},{"issue":"167","key":"10.1016\/j.expneurol.2022.114288_bb0035","article-title":"Validated animal models for antiseizure drug (ASD) discovery: advantages and potential pitfalls in ASD screening","volume":"1","author":"Barker-Haliski","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2022.114288_bb0075","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","article-title":"Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy","volume":"47","author":"Barton","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.expneurol.2022.114288_bb0080","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1111\/epi.16725","article-title":"Progress report on new antiepileptic drugs: a summary of the fifteenth Eilat conference on new antiepileptic drugs and devices (EILAT XV). I. Drugs in preclinical and early clinical development","volume":"61","author":"Bialer","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114288_bb0085","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1111\/epi.16726","article-title":"Progress report on new antiepileptic drugs: a summary of the fifteenth Eilat conference on new antiepileptic drugs and devices (EILAT XV). II. Drugs in more advanced clinical development","volume":"61","author":"Bialer","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114288_bb0090","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1528-1157.1953.tb03315.x","article-title":"Properties and alterations of electrically-induced seizures in mice","volume":"2","author":"Brown","year":"1953","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114288_bb0095","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1113\/jphysiol.2010.187484","article-title":"NaV1.1 channels and epilepsy","volume":"588","author":"Catterall","year":"2010","journal-title":"J. Physiol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0100","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/1359-6446(96)10039-8","article-title":"Physicochemical and drug-delivery considerations for oral drug bioavailability","volume":"1","author":"Chan","year":"1996","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.expneurol.2022.114288_bb0105","doi-asserted-by":"crossref","first-page":"14646","DOI":"10.1073\/pnas.1211591109","article-title":"Specific deletion of NaV1.1 sodium channels in inhibitory interneurons causes seizures and premature death in a mouse model of Dravet syndrome","volume":"109","author":"Cheah","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2022.114288_bb0110","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1523\/JNEUROSCI.3966-06.2007","article-title":"Prevention of plasticity of endocannabinoid signaling inhibits persistent limbic hyperexcitability caused by developmental seizures","volume":"27","author":"Chen","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2022.114288_bb0115","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0120","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/humu.10217","article-title":"De novo SCN1A mutations are a major cause of severe myoclonic epilepsy of infancy","volume":"21","author":"Claes","year":"2003","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.expneurol.2022.114288_bb0125","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0022-3565(25)30824-4","article-title":"Cannabidiol--antiepileptic drug comparisons and interactions in experimentally induced seizures in rats","volume":"201","author":"Consroe","year":"1977","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2022.114288_bb0130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000137430","article-title":"Chronic administration of cannabidiol to healthy volunteers and epileptic patients","volume":"21","author":"Cunha","year":"1980","journal-title":"Pharmacology"},{"key":"10.1016\/j.expneurol.2022.114288_bb0135","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/JVI.02747-12","article-title":"Infiltrating macrophages are key to the development of seizures following virus infection","volume":"87","author":"Cusick","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0140","doi-asserted-by":"crossref","first-page":"11286","DOI":"10.1038\/s41598-022-15134-5","article-title":"Effects of chronic cannabidiol in a mouse model of naturally occurring neuroinflammation, neurodegeneration, and spontaneous seizures","volume":"12","author":"Dearborn","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.expneurol.2022.114288_bb0145","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00213-011-2415-0","volume":"219","author":"Deiana","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.expneurol.2022.114288_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.833624","article-title":"Can old animals reveal new targets? The aging and degenerating brain as a new precision medicine opportunity for epilepsy","volume":"13","author":"Del Pozo","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0155","first-page":"464","article-title":"The immune response to picornavirus infection and the effect of immune manipulation on acute seizures","volume":"24","author":"DePaula-Silva","year":"2018","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0160","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.tins.2012.11.008","article-title":"Glia and epilepsy: excitability and inflammation","volume":"36","author":"Devinsky","year":"2013","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.expneurol.2022.114288_bb0165","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0170","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of Cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2022.114288_bb0175","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMc1708349","article-title":"Trial of Cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"377","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2022.114288_bb0180","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2022.114288_bb0185","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/epi.14628","article-title":"Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial","volume":"60","author":"Devinsky","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114288_bb0190","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fphar.2017.00131","article-title":"Protective effects of Cannabidiol against seizures and neuronal death in a rat model of mesial temporal lobe epilepsy","volume":"8","author":"Do Val-da Silva","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0195","first-page":"71","article-title":"Severe myoclonic epilepsy in infancy: Dravet syndrome","volume":"95","author":"Dravet","year":"2005","journal-title":"Adv. Neurol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0200","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1111\/epi.16973","article-title":"Antiseizure effects of the cannabinoids in the amygdala-kindling model","volume":"62","author":"Fallah","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114288_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108442","article-title":"Cannabidiol in the treatment of epilepsy: current evidence and perspectives for further research","volume":"185","author":"Franco","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2022.114288_bb0210","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.nbd.2015.04.015","article-title":"Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: a view from preclinical studies","volume":"79","author":"Galanopoulou","year":"2015","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2022.114288_bb0215","doi-asserted-by":"crossref","first-page":"187","DOI":"10.5698\/1535-7511-16.3.187","article-title":"2014 epilepsy benchmarks area II: prevent epilepsy and its progression","volume":"16","author":"Galanopoulou","year":"2016","journal-title":"Epilepsy Curr.\/Am. Epilepsy Soc."},{"key":"10.1016\/j.expneurol.2022.114288_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10081811","article-title":"Anticonvulsant action and long-term effects of chronic Cannabidiol treatment in the rat Pentylenetetrazole-kindling model of epilepsy","volume":"10","author":"Gall","year":"2022","journal-title":"Biomedicines"},{"issue":"Suppl. 2","key":"10.1016\/j.expneurol.2022.114288_bb0225","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1528-1167.2011.03001.x","article-title":"Dravet syndrome: the long-term outcome","volume":"52","author":"Genton","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114288_bb0230","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/0883073816669450","article-title":"Cannabidiol as a potential treatment for febrile infection-related epilepsy syndrome (FIRES) in the acute and chronic phases","volume":"32","author":"Gofshteyn","year":"2017","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0235","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/can.2019.0028","article-title":"Anticonvulsive properties of Cannabidiol in a model of generalized seizure are transient receptor potential Vanilloid 1 dependent","volume":"5","author":"Gray","year":"2020","journal-title":"Cannabis Cannabinoid. Res."},{"key":"10.1016\/j.expneurol.2022.114288_bb0240","first-page":"669","article-title":"Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome","volume":"140","author":"Griffin","year":"2017","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0245","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1172\/JCI130419","article-title":"Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice","volume":"129","author":"Gu","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.expneurol.2022.114288_bb0250","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1111\/epi.17062","article-title":"Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice","volume":"62","author":"Hawkins","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114288_bb0255","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1111\/j.1476-5381.2012.02207.x","article-title":"Cannabidivarin is anticonvulsant in mouse and rat","volume":"167","author":"Hill","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0260","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bph.12321","article-title":"Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism","volume":"170","author":"Hill","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0265","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.nbd.2016.12.007","article-title":"Blockade of the IL-1R1\/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy","volume":"99","author":"Iori","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2022.114288_bb0270","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1124\/jpet.109.159145","article-title":"Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo","volume":"332","author":"Jones","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2022.114288_bb0275","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.seizure.2012.03.001","article-title":"Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures","volume":"21","author":"Jones","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.expneurol.2022.114288_bb0280","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1172\/JCI66220","article-title":"Sudden unexpected death in a mouse model of Dravet syndrome","volume":"123","author":"Kalume","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.expneurol.2022.114288_bb0285","doi-asserted-by":"crossref","first-page":"11229","DOI":"10.1073\/pnas.1711351114","article-title":"Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome","volume":"114","author":"Kaplan","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2022.114288_bb0290","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1476-5381.1980.tb14562.x","article-title":"Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice","volume":"68","author":"Karler","year":"1980","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0295","doi-asserted-by":"crossref","first-page":"437S","DOI":"10.1002\/j.1552-4604.1981.tb02624.x","article-title":"The cannabinoids as potential antiepileptics","volume":"21","author":"Karler","year":"1981","journal-title":"J. Clin. Pharmacol."},{"issue":"7","key":"10.1016\/j.expneurol.2022.114288_bb0300","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1007\/s11064-017-2275-z","article-title":"The National Institute of Neurological Disorders and Stroke (NINDS) epilepsy therapy screening program (ETSP)","volume":"42","author":"Kehne","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.expneurol.2022.114288_bb0305","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1528-1167.2009.02390.x","article-title":"Innate but not adaptive immune responses contribute to behavioral seizures following viral infection","volume":"51","author":"Kirkman","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114288_bb0310","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s11064-017-2287-8","article-title":"Evaluation of Cannabidiol in animal seizure models by the epilepsy therapy screening program (ETSP)","volume":"42","author":"Klein","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.expneurol.2022.114288_bb0315","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/epi.13965","article-title":"Commonalities in epileptogenic processes from different acute brain insults: do they translate?","volume":"59","author":"Klein","year":"2018","journal-title":"Epilepsia"},{"issue":"Suppl. 4","key":"10.1016\/j.expneurol.2022.114288_bb0320","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1528-1167.2001.00003.x","article-title":"Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?","volume":"42","author":"Klitgaard","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114288_bb0325","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0014-2999(98)00410-5","article-title":"Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy","volume":"353","author":"Klitgaard","year":"1998","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0330","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.neuro.2020.12.002","article-title":"Cannabidiol reduces soman-induced lethality and seizure severity in female plasma carboxylesterase knockout mice treated with midazolam","volume":"82","author":"Kundrick","year":"2021","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.expneurol.2022.114288_bb0335","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40495-021-00270-9","article-title":"Neuroinflammation in epilepsy\u2014diagnostics and therapeutic perspectives","author":"Lach","year":"2022","journal-title":"Curr. Pharmacol. Reports"},{"key":"10.1016\/j.expneurol.2022.114288_bb0340","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1055\/s-2008-1040854","article-title":"Susceptibility genes in human epilepsy","volume":"19","author":"Leppert","year":"1999","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0345","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/j.1528-1167.2008.01535.x","article-title":"Seizures following picornavirus infection","volume":"49","author":"Libbey","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114288_bb0350","doi-asserted-by":"crossref","first-page":"6913","DOI":"10.1128\/JVI.00458-11","article-title":"Interleukin-6, produced by resident cells of the central nervous system and infiltrating cells, contributes to the development of seizures following viral infection","volume":"85","author":"Libbey","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0355","first-page":"496","article-title":"Once initiated, viral encephalitis-induced seizures are consistent no matter the treatment or lack of interleukin-6","volume":"17","author":"Libbey","year":"2011","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0360","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eplepsyres.2016.05.016","article-title":"Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies","volume":"126","author":"Loscher","year":"2016","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.expneurol.2022.114288_bb0365","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s11064-017-2222-z","article-title":"Animal models of seizures and epilepsy: past, present, and future role for the discovery of Antiseizure drugs","volume":"42","author":"Loscher","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.expneurol.2022.114288_bb0370","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1007\/s11064-016-2025-7","article-title":"The search for new screening models of Pharmacoresistant epilepsy: is induction of acute seizures in epileptic rodents a suitable approach?","volume":"42","author":"Loscher","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.expneurol.2022.114288_bb0375","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrd4126","article-title":"New avenues for anti-epileptic drug discovery and development","volume":"12","author":"Loscher","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.expneurol.2022.114288_bb0380","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/epi.16974","article-title":"Time to onset of cannabidiol treatment effects in Dravet syndrome: analysis from two randomized controlled trials","volume":"62","author":"Madan Cohen","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114288_bb0385","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1088208","article-title":"CB1 cannabinoid receptors and on-demand defense against excitotoxicity","volume":"302","author":"Marsicano","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2022.114288_bb0390","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.yebeh.2007.02.001","article-title":"Kindling epileptogenesis in immature rats leads to persistent depressive behavior","volume":"10","author":"Mazarati","year":"2007","journal-title":"Epilepsy Behav.: E&B"},{"key":"10.1016\/j.expneurol.2022.114288_bb0395","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.expneurol.2017.08.009","article-title":"Scavenging reactive oxygen species inhibits status epilepticus-induced neuroinflammation","volume":"298","author":"McElroy","year":"2017","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0400","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3389\/fphar.2018.01365","article-title":"A systematic review on the pharmacokinetics of Cannabidiol in humans","volume":"9","author":"Millar","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0405","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive Oral Cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0410","doi-asserted-by":"crossref","first-page":"17081","DOI":"10.1038\/s41598-020-74036-6","article-title":"Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice","volume":"10","author":"Nishi","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.expneurol.2022.114288_bb0415","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/epi.17232","article-title":"Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor","volume":"63","author":"Nishi","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114288_bb0420","unstructured":"Office, L.P.A.R., 2021. Background Brief MEASURE 110 (2020), in: Oregon, S.O. (Ed.), Salem, OR, USA."},{"key":"10.1016\/j.expneurol.2022.114288_bb0425","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1523\/JNEUROSCI.5270-06.2007","article-title":"Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation","volume":"27","author":"Ogiwara","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2022.114288_bb0430","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1523\/JNEUROSCI.4314-05.2006","article-title":"A common ankyrin-G-based mechanism retains KCNQ and NaV channels at electrically active domains of the axon","volume":"26","author":"Pan","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2022.114288_bb0435","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/epi4.12351","article-title":"Cannabidiol reduces seizures following CNS infection with Theiler's murine encephalomyelitis virus","volume":"4","author":"Patel","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.expneurol.2022.114288_bb0440","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1093\/brain\/aww129","article-title":"Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol","volume":"139","author":"Patel","year":"2016","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0445","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/epi.14629","article-title":"Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models","volume":"60","author":"Patra","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114288_bb0450","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1111\/bph.15003","article-title":"Cannabidiol improves survival and behavioural co-morbidities of Dravet syndrome in mice","volume":"177","author":"Patra","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.expneurol.2022.114288_bb0455","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awz130","article-title":"Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy","volume":"142","author":"Pauletti","year":"2017","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0460","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/epi.16925","article-title":"Development of an antiseizure drug screening platform for Dravet syndrome at the NINDS contract site for the epilepsy therapy screening program","volume":"62","author":"Pernici","year":"2021","journal-title":"Epilepsia"},{"issue":"Suppl. 1","key":"10.1016\/j.expneurol.2022.114288_bb0465","first-page":"S163","article-title":"Cannabinoid pharmacology: the first 66 years","volume":"147","author":"Pertwee","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0470","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0022-3565(25)20907-7","article-title":"Effect of stimulus intensity on the profile of anticonvulsant activity of phenytoin, ethosuximide and valproate","volume":"232","author":"Piredda","year":"1985","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2022.114288_bb0475","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.yebeh.2013.08.037","article-title":"Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy","volume":"29","author":"Porter","year":"2013","journal-title":"Epilepsy & Behav.: E&B"},{"key":"10.1016\/j.expneurol.2022.114288_bb0480","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejpn.2022.01.008","article-title":"Is cannabidiol worth a trial in Rasmussen encephalitis?","volume":"37","author":"Prager","year":"2022","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0485","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1126\/science.85.2213.525","article-title":"Experimental determination of the anticonvulsant properties of some phenyl derivatives","volume":"85","author":"Putnam","year":"1937","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2022.114288_bb0490","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.expneurol.2015.07.001","article-title":"JAK\/STAT pathway regulation of GABAA receptor expression after differing severities of experimental TBI","volume":"271","author":"Raible","year":"2015","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0495","article-title":"Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies","volume":"359","author":"Reddy","year":"2022","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0500","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/ejn.15096","article-title":"Dissociable changes in spike and wave discharges following exposure to injected cannabinoids and smoked cannabis in genetic absence epilepsy rats from Strasbourg","volume":"55","author":"Roebuck","year":"2022","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2022.114288_bb0505","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s13311-015-0375-5","article-title":"Cannabinoids and epilepsy","volume":"12","author":"Rosenberg","year":"2015","journal-title":"Neurotherap.: J. Am. Soc. Exper. NeuroTherap."},{"key":"10.1016\/j.expneurol.2022.114288_bb0510","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.pbb.2011.10.005","article-title":"Inverse relationship of cannabimimetic (R+)WIN 55, 212 on behavior and seizure threshold during the juvenile period","volume":"100","author":"Rudenko","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.expneurol.2022.114288_bb0515","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.815950","article-title":"Cannabidiol increases seizure resistance and improves behavior in an Scn8a mouse model","volume":"13","author":"Shapiro","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.107966","article-title":"Mechanisms of action of currently used antiseizure drugs","volume":"168","author":"Sills","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2022.114288_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107733","article-title":"Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies","volume":"158","author":"Socala","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2022.114288_bb0530","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0014-2999(76)90295-8","article-title":"Anticonvulsant activity of delta9-tetrahydrocannabinol compared with three other drugs","volume":"35","author":"Sofia","year":"1976","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0535","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/ana.21603","article-title":"Anticonvulsant and antiepileptic actions of 2-deoxy-D-glucose in epilepsy models","volume":"65","author":"Stafstrom","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0540","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/jcph.1412","article-title":"A phase 1, open-label, parallel-group, single-dose trial of the pharmacokinetics and safety of Cannabidiol (CBD) in subjects with mild to severe hepatic impairment","volume":"59","author":"Taylor","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0545","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.expneurol.2022.114288_bb0550","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1212\/WNL.1.11-12.444","article-title":"Neuropharmacologic considerations in psychic seizures","volume":"1","author":"Toman","year":"1951","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2022.114288_bb0555","first-page":"96","article-title":"The search for new drugs against epilepsy","volume":"10","author":"Toman","year":"1952","journal-title":"Tex. Rep. Biol. Med."},{"key":"10.1016\/j.expneurol.2022.114288_bb0560","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/WCO.0000000000001029","article-title":"New and emerging pharmacologic treatments for developmental and epileptic encephalopathies","volume":"35","author":"Vasquez","year":"2022","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0565","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.yebeh.2017.07.014","article-title":"Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels","volume":"75","author":"Vilela","year":"2017","journal-title":"Epilepsy Behav.: E&B"},{"key":"10.1016\/j.expneurol.2022.114288_bb0570","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0014-2999(01)01243-2","article-title":"Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects","volume":"428","author":"Wallace","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0575","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.eplepsyres.2015.06.003","article-title":"Validation of the 6 Hz refractory seizure mouse model for intracerebroventricularly administered compounds","volume":"115","author":"Walrave","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.expneurol.2022.114288_bb0580","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.nbd.2017.12.001","article-title":"Macrophage depletion by liposome-encapsulated clodronate suppresses seizures but not hippocampal damage after acute viral encephalitis","volume":"110","author":"Waltl","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2022.114288_bb0585","series-title":"The Treatment of Epilepsy","first-page":"52","article-title":"Antiepileptic drug discovery","author":"White","year":"2016"},{"key":"10.1016\/j.expneurol.2022.114288_bb0590","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-94-017-8914-1_14","article-title":"Does brain inflammation mediate pathological outcomes in epilepsy?","volume":"813","author":"Wilcox","year":"2014","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.expneurol.2022.114288_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107811","article-title":"The current approach of the epilepsy therapy screening program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy","volume":"166","author":"Wilcox","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2022.114288_bb0600","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/nn1754","article-title":"Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy","volume":"9","author":"Yu","year":"2006","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.expneurol.2022.114288_bb0605","article-title":"Cannabidiol activates neuronal Kv7 channels","volume":"11","author":"Zhang","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.expneurol.2022.114288_bb0610","article-title":"Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramine","volume":"10","author":"Zhang","year":"2015","journal-title":"PLoS One"}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488622003132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488622003132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T06:12:28Z","timestamp":1758003148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488622003132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":122,"alternative-id":["S0014488622003132"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2022.114288","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2022.114288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114288"}}